JP2012184264A5 - - Google Patents

Download PDF

Info

Publication number
JP2012184264A5
JP2012184264A5 JP2012148640A JP2012148640A JP2012184264A5 JP 2012184264 A5 JP2012184264 A5 JP 2012184264A5 JP 2012148640 A JP2012148640 A JP 2012148640A JP 2012148640 A JP2012148640 A JP 2012148640A JP 2012184264 A5 JP2012184264 A5 JP 2012184264A5
Authority
JP
Japan
Prior art keywords
composition
administered
subject
dose
viral infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012148640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012184264A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012184264A publication Critical patent/JP2012184264A/ja
Publication of JP2012184264A5 publication Critical patent/JP2012184264A5/ja
Withdrawn legal-status Critical Current

Links

JP2012148640A 2004-06-24 2012-07-02 免疫増強用の化合物 Withdrawn JP2012184264A (ja)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US58265404P 2004-06-24 2004-06-24
US60/582,654 2004-06-24
US58809604P 2004-07-14 2004-07-14
US60/588,096 2004-07-14
US59045904P 2004-07-22 2004-07-22
US60/590,459 2004-07-22
US59959204P 2004-08-05 2004-08-05
US59971704P 2004-08-05 2004-08-05
US60/599,717 2004-08-05
US60/599,592 2004-08-05
US60085004P 2004-08-11 2004-08-11
US60/600,850 2004-08-11
US60300104P 2004-08-19 2004-08-19
US60/603,001 2004-08-19
US60386704P 2004-08-23 2004-08-23
US60/603,867 2004-08-23
US61207004P 2004-09-21 2004-09-21
US60/612,070 2004-09-21
US60/614,963 2004-09-21
US61496304P 2004-09-30 2004-09-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007518351A Division JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物

Publications (2)

Publication Number Publication Date
JP2012184264A JP2012184264A (ja) 2012-09-27
JP2012184264A5 true JP2012184264A5 (enExample) 2012-11-08

Family

ID=35601821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007518351A Withdrawn JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物
JP2012148640A Withdrawn JP2012184264A (ja) 2004-06-24 2012-07-02 免疫増強用の化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007518351A Withdrawn JP2008504292A (ja) 2004-06-24 2005-06-24 免疫増強用の化合物

Country Status (4)

Country Link
EP (2) EP1765313A2 (enExample)
JP (2) JP2008504292A (enExample)
CA (1) CA2571421A1 (enExample)
WO (1) WO2006002422A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504286A (ja) * 2004-06-24 2008-02-14 カイロン コーポレイション 小分子免疫増強因子およびその検出のためのアッセイ
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
WO2007052056A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
NZ567981A (en) 2005-11-04 2011-10-28 Novartis Vaccines & Diagnostic Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009515839A (ja) * 2005-11-15 2009-04-16 メルク フロスト カナダ リミテツド ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体
WO2007068116A1 (en) * 2005-12-13 2007-06-21 Mcgill University Method for correcting a lipid imbalance in a subject
WO2007071402A1 (en) * 2005-12-23 2007-06-28 Jado Technologies Gmbh Means and methods for the treatment and prevention of allergic diseases
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
MX2008015765A (es) * 2006-07-27 2009-03-26 Cv Therapeutics Inc Inhibidores de aldh-2 en el tratamiento de adiccion.
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
AU2007330494B2 (en) 2006-12-06 2014-03-13 Seqirus UK Limited Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2152719A4 (en) * 2007-05-23 2011-01-19 Merck Frosst Canada Ltd BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
SI2185191T1 (sl) 2007-06-27 2012-12-31 Novartis Ag Cepiva proti influenci z majhnimi dodatki
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
BRPI0822129A2 (pt) * 2008-01-24 2015-06-23 Gilead Palo Alto Inc Inibidores de aldh-2c no tratamento de vício.
ES2326459B1 (es) * 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
CN102227237A (zh) * 2008-09-26 2011-10-26 国家健康与医学研究院 作为针对hcv感染的抗病毒治疗的靶标的宿主细胞激酶
WO2010072155A1 (zh) * 2008-12-26 2010-07-01 复旦大学 一种嘧啶类衍生物及其制备方法和用途
JP5829210B2 (ja) 2009-07-15 2015-12-09 ノバルティス アーゲー Ｒｓｖｆタンパク質組成物およびそれを作製するための方法
CN101774994B (zh) * 2009-08-21 2012-05-23 南京大学中国医药城研发中心 白杨素长链衍生物及其制备方法与用途
CN102946881A (zh) * 2010-04-23 2013-02-27 奇尼塔公司 抗病毒化合物
EP2637650A2 (en) * 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
CN102552271B (zh) * 2010-12-09 2014-08-06 中国科学院上海药物研究所 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途
SI2667892T1 (sl) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Imunizacijski režim proti RSV
WO2012154271A2 (en) 2011-02-25 2012-11-15 Kineta, Inc. Method and cells for identifying rig-i pathway regulators
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2016046734A2 (en) * 2014-09-22 2016-03-31 University Of The Western Cape Compounds and compositions for treatment of tuberculosis
DE102014017368A1 (de) 2014-11-24 2015-05-28 Clariant International Ltd. Verwendung von Polyhydroxyfettsäureamiden zur Verbesserung der Nassabriebbeständigkeit von wässrigen Dispersionsfarben
DE202014010366U1 (de) 2014-11-24 2015-05-15 Clariant International Ltd. Verwendung von Polyhydroxyfettsäureamiden zur Verbesserung der Nassabriebbeständigkeit von wässrigen Dispersionen
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109232573A (zh) * 2018-08-24 2019-01-18 江苏理工学院 一种化合物b1作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223793B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c1作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109053544B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b11作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223796B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223795B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物b2作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN109400567A (zh) * 2018-12-05 2019-03-01 华中药业股份有限公司 一种合成甘草素的方法
EP3725788A1 (en) 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN112300228A (zh) * 2020-10-31 2021-02-02 青岛姿之妍化妆品科技有限责任公司 一种包括含有根皮三酚基团的根皮素衍生物的化妆品及其制备方法
CN112125940B (zh) * 2020-10-31 2025-10-21 青岛姿之妍化妆品科技有限责任公司 含有四乙酰葡萄糖苷改性的根皮素的化妆品及其制备方法
CN119859132A (zh) * 2023-10-20 2025-04-22 中国石油化工股份有限公司 一种环烃类白杨素衍生物及其制备方法
CN118580289B (zh) * 2024-06-21 2025-05-13 海南大学 一种具有抗肿瘤作用的化合物bp220805及其制备方法和应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (enExample) 1957-05-07
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
DE3768232D1 (de) 1986-12-19 1991-04-04 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
WO1989007105A1 (fr) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2011896C (en) 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
WO1990014357A1 (en) 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
US5439936A (en) 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5284652A (en) 1990-10-26 1994-02-08 Pier Allan C Dermatophyte vaccine
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
EP0610433A1 (en) 1991-11-08 1994-08-17 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
WO1993010814A1 (en) 1991-11-29 1993-06-10 Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
WO1994006799A1 (en) 1992-09-21 1994-03-31 Kyowa Hakko Kogyo Co., Ltd. Thrombocytopenia remedy
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EP0817627B1 (en) 1993-12-23 2005-03-09 Eli Lilly And Company Protein kinase c inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
CN1101392C (zh) 1995-12-08 2003-02-12 詹森药业有限公司 抑制法呢基蛋白质转移酶的(咪唑－5－基)甲基－2－喹啉酮衍生物
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
EP0934336A1 (en) 1996-05-14 1999-08-11 Smithkline Beecham Corporation Novel compounds
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
EP0970966B1 (en) 1996-09-04 2008-02-20 Takara Bio Inc. Fungal antigens and process for producing the same
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69819150T3 (de) 1997-06-06 2007-12-20 Dynavax Technologies Corp., San Diego Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US5948413A (en) 1997-07-17 1999-09-07 Board Of Trustees Operating Michigan State University Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
CN100390283C (zh) 1997-11-21 2008-05-28 根瑟特公司 肺炎衣原体的基因组序列和其多肽,片段以及其用途特别是用于诊断、预防和治疗感染
KR100735653B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
AP1393A (en) 1998-09-30 2005-04-19 Wrair Walter Reid Army Institute Of Res Indolo [2,1-b] quinazole-6, 12-dione antimalarial compounds and methods of treating malaria therewith.
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
IL142395A0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE346608T1 (de) 1999-03-19 2006-12-15 Glaxosmithkline Biolog Sa Impstoff gegen streptococcus pneumoniae
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2000067161A2 (en) 1999-05-04 2000-11-09 Grant Lee H Method and apparatus for categorizing and retrieving network pages and sites
CA2379035A1 (en) 1999-07-13 2001-01-18 Shiro Akinaga Staurosporin derivatives
WO2001008636A2 (en) 1999-08-03 2001-02-08 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
MXPA02003067A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas.
MXPA02003068A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Adyuvante que comprende un eter o ester alquilo de polioxietileno y al menos un tensioactivo no ionico..
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
CN1329390C (zh) 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
JP2003531148A (ja) 2000-04-12 2003-10-21 ジェネーラ・コーポレーション 保護されていない７−α−ヒドロキシ基を有する中間体を使用する、７−α−ヒドロキシ３−アミノ置換ステロイドの調製のためのプロセス
ES2280382T3 (es) 2000-06-30 2007-09-16 Glaxo Group Limited Compuestos de las sales ditosilato de quinazolina.
WO2002016351A1 (en) * 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Quinazoline derivatives as kinase inhibitors
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
CA2447599C (en) 2001-05-18 2015-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US6900342B2 (en) 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
PT1551357E (pt) 2002-09-13 2014-10-10 Novartis Vaccines & Diagnostic Vacina contra os estreptococos do grupo b
JPWO2004026341A1 (ja) * 2002-09-19 2006-01-12 株式会社オリエントキャンサーセラピー ガンの免疫治療剤
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes

Similar Documents

Publication Publication Date Title
JP2012184264A5 (enExample)
CN113748114A (zh) 一种喹唑啉化合物及其在医药上的应用
JP2019526596A5 (enExample)
JP2016040288A5 (enExample)
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
JP2013520167A5 (enExample)
JP2015512931A5 (enExample)
JP2013540000A5 (enExample)
JP2015505296A5 (enExample)
JP2013241424A5 (enExample)
JP2020097577A5 (enExample)
JP2015500843A5 (enExample)
JP2014503206A5 (enExample)
HK1212235A1 (en) Antiviral azasugar-containing nucleosides
JP2014509612A5 (enExample)
JP2016510326A5 (enExample)
JP2011246469A5 (enExample)
EP2444103A4 (en) UTERUS COLON CANCER VACCINE
JP2015514115A5 (enExample)
JP2013542981A5 (enExample)
JP2016128507A5 (enExample)
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2012162567A5 (enExample)
JP2017532316A5 (enExample)
JP2016500703A5 (enExample)